| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Hemoglobin Electrophoresis
MessageSendout, Mayo test code: HBEL1
Test Code
LAB2900
Alias/See Also
A2 Hemoglobin
Alpha Globin Variant
Alpha Thalassemia
Barts Hemoglobin
Beta Globin Variant
Beta Thalassemia
H Disease
Hemoglobin A2
Hemoglobin Cascade
Hemoglobin Electrophoresis Cascade Level 1
Hemoglobin Molecular studies
Hemoglobin Variant
HGB (Hemoglobin) Electrophoresis
Isoelectric Focusing
Capillary electrophoresis
HPLC
High performance liquid chromatography
Mass Spectrometry
Microcytosis
Sickle cell
Sickling Test
Thalassemia
HBEL1
Alpha Globin Variant
Alpha Thalassemia
Barts Hemoglobin
Beta Globin Variant
Beta Thalassemia
H Disease
Hemoglobin A2
Hemoglobin Cascade
Hemoglobin Electrophoresis Cascade Level 1
Hemoglobin Molecular studies
Hemoglobin Variant
HGB (Hemoglobin) Electrophoresis
Isoelectric Focusing
Capillary electrophoresis
HPLC
High performance liquid chromatography
Mass Spectrometry
Microcytosis
Sickle cell
Sickling Test
Thalassemia
HBEL1
CPT Codes
83020, 83021, 82664 (if appropriate), 83068 (if appropriate), 83789 (if appropriate), 88184 (if appropriate), 83020-26 (if appropriate)
Preferred Specimen
10 mL whole blood in a lavender EDTA tube.
Minimum Volume
1 mL (this volume will limit reflex testing possibilities.
3 mL if multiplex ligation-dependent probe amplification is needed.
3 mL if multiplex ligation-dependent probe amplification is needed.
Other Acceptable Specimens
Yellow ACD (solution B), green tube (sodium heparin)
Instructions
Send whole blood specimen in original tube. Do not aliquot.
Transport Container
Original tube
Transport Temperature
Refrigerated
Specimen Stability
Refrigerated 7 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.
Methodology
A2F: Cation Exchange/High-Performance Liquid Chromatography (HPLC) HBEL: Capillary Electrophoresis IEF: Isoelectric Focusing MASS: Mass Spectrometry (MS) HGBMO: Polymerase Chain Reaction (PCR) Analysis/Multiplex Ligation-Dependent Probe Amplification
FDA Status
Approved
Setup Schedule
Monday through Thursday
Report Available
2-25 days
Limitations
Some hemoglobin disorders and variants are not detected by the screening methods including, common alpha-thalassemia conditions and require further reflex testing to identify. If a family history of a known hemoglobin disorder, prior therapy for a hemoglobin disorder, or otherwise unexplained lifelong/familial symptoms, such as hemolysis, microcytosis, erythrocytosis/polycythemia, cyanosis, or hypoxia are present, this should be clearly communicated to the laboratory so appropriate reflex testing can be added, see Metabolic Hematology Patient Information.
Recent transfusion may mask protein results including hemoglobin electrophoresis, hereditary persistence of hemoglobin F by flow cytometry, stability studies, and sickle solubility studies depending on percentage of transfused cells present.
Some hemoglobin variants can originate from the donor blood product and not from the tested recipient. These are typically found in low percentage.
If the patient has undergone a bone marrow transplant, the results may show atypical results and should be interpreted in the context of clinical information.
Some therapies cause artefactual effects in protein studies, including hydroxyurea and decitabine (increased hemoglobin F levels), voxelotor (artefactual peaks) and gene therapy (alternate protein detection, beta T87Q, by mass spectrometry). Clear communication of prior therapy is strongly recommended.
Recent transfusion may mask protein results including hemoglobin electrophoresis, hereditary persistence of hemoglobin F by flow cytometry, stability studies, and sickle solubility studies depending on percentage of transfused cells present.
Some hemoglobin variants can originate from the donor blood product and not from the tested recipient. These are typically found in low percentage.
If the patient has undergone a bone marrow transplant, the results may show atypical results and should be interpreted in the context of clinical information.
Some therapies cause artefactual effects in protein studies, including hydroxyurea and decitabine (increased hemoglobin F levels), voxelotor (artefactual peaks) and gene therapy (alternate protein detection, beta T87Q, by mass spectrometry). Clear communication of prior therapy is strongly recommended.
Reference Range
Included with report
Clinical Significance
Diagnosis and classification of hemoglobin disorders, including thalassemias and hemoglobin variants
Performing Laboratory
Mayo Clinic Laboratories, Rochester, Minnesota
Additional Information
Hemoglobin Electrophoresis Evaluation, Blood
